Kazia Therapeutics Limited
Kazia Therapeutics Limited (KZIA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
kzia · pe ratio · data through Jun 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Kazia Therapeutics Limited (KZIA) measures how much investors pay for each dollar of the company's trailing earnings. KZIA's current PE ratio of N/A is calculated by dividing its stock price of $11.40 by its TTM earnings per share of -$7.14.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-06-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Kazia Therapeutics LimitedYou KZIA | $18M | N/A | — | -$7.14 |
 Biodexa Pharmaceuticals Plc BDRX | $1M | N/A | — | -$113.82 |
 Can-Fite BioPharma Ltd. CANF | $2M | N/A | — | -$12.02 |
 Clearmind Medicine Inc. CMND | $4M | N/A | — | -$3.03 |
 CNS Pharmaceuticals, Inc. CNSP | $3M | N/A | — | -$35.75 |
 GRI Bio, Inc. GRI | $0M | N/A | — | -$121.80 |
 InMed Pharmaceuticals Inc. INM | $3M | N/A | — | -$8.36 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-06-30Latest FY2025 | — | $-18.90 | — | |
2024-06-30 FY2024 | — | $-55.83 | — | |
2023-06-30 FY2023 | — | $-55.52 | — | |
2022-06-30 FY2022 | — | $-94.39 | — | |
2021-06-30 FY2021 | — | $-35.77 | — | |
2020-06-30 FY2020 | — | $-81.78 | — | |
2019-06-30 FY2019 | — | $-85.58 | — | |
2018-06-30 FY2018 | — | $-59.82 | — | |
2017-06-30 FY2017 | — | $-109.29 | — | |
2016-06-30 FY2016 | — | $-135.22 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Kazia Therapeutics Limited (KZIA) measures how much investors pay for each dollar of the company's trailing earnings. KZIA's current PE ratio of N/A is calculated by dividing its stock price of $11.40 by its TTM earnings per share of -$7.14.
Frequently asked questions
KZIA pe ratio · 6 questionsKZIA's current PE ratio is N/A as of 2026-06-08, based on a stock price of $11.40 and TTM EPS of -$7.14. Data sourced from Financial Modeling Prep via KZIA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Kazia Therapeutics Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08